Davis Gregory D 4

What Happened
Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), sold 69,827 shares on April 22, 2026. The filing reports a weighted-average sale price of $0.25 per share for total proceeds of $17,694. The Form 4 indicates these were open-market sales (code "S").

Key Details

• Transaction date: 2026-04-22; Form 4 filed 2026-04-23 (filed next day).
• Reported price: weighted-average $0.25 per share; footnote states individual sale prices ranged from $0.2533 to $0.2568.
• Shares sold: 69,827; proceeds reported: $17,694.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The reported price is a weighted average; the filer can provide the number of shares sold at each separate price on request (SEC staff, issuer, or security holders).
• Filing timeliness: filed the day after the trade (consistent with typical Form 4 timing).

Context
This was a sale, which for insiders can be routine (e.g., portfolio rebalancing or liquidity needs) and does not by itself indicate management opinion on the company. There was no option exercise, award, or gift involved in this transaction. If you track insider buying as a stronger signal of confidence, note this is a sale and not a bullish purchase.